MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Tirzepatide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Tirzepatide (Eli Lilly's Mounjaro and Zepbound) is a once-weekly dual agonist at the GIP and GLP-1 receptors — the first incretin-class drug to clearly outperform pure GLP-1 monotherapy in head-to-head trials. GLP-1 activation reduces appetite, slows gastric emptying and enhances glucose-dependent insulin secretion; the added GIP arm augments satiety and improves adipose-tissue insulin sensitivity. In the pivotal SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), tirzepatide 15 mg produced mean weight loss of 20.9% at 72 weeks, and in SURPASS-2 (Frias et al., NEJM 2021) it beat semaglutide 1 mg on both HbA1c (-2.30% vs -1.86%) and weight (-11.2 kg vs -5.7 kg) [1][3]. FDA approved for type 2 diabetes in May 2022 (Mounjaro) and chronic weight management in November 2023 (Zepbound), with subsequent approvals across the EU, UK, Japan and China.
Reconstitute: Add 2 mL bacteriostatic water → 2.5 mg/mL concentration.
Typical dose: 2.5–15 mg once weekly (gradual 4‑week titration steps).
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 0.0250 mg (25 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Half-life: Approximately 5 days, allowing fixed once-weekly subcutaneous dosing; full pharmacokinetic steady-state is reached after roughly 4 weeks of consecutive injections [1].
Approval status: FDA approved as Mounjaro (T2D, May 2022) and Zepbound (chronic weight management, November 2023). Approved across the EU, UK, Japan, China and most major markets.
Beyond weight loss: SURMOUNT-OSA halved the apnea-hypopnea index in obese adults with moderate-to-severe sleep apnea, and SUMMIT cut the composite of cardiovascular death and worsening heart failure by 38% in obesity-related HFpEF.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
Interactive Tirzepatide Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 2mL water yields 2.50 mg/mL. To evaluate a 250mcg dose, pull to 10.0 units (10 syringe ticks).
U-100 Syringe Representation
10.0 Units (10 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Weekly Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 units (1.0 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 100 units (1.0 mL) × 2 injections |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) × 3 injections |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 4 injections |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (Tirzepatide, 5 mg each):
- check8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 6 vials
- check12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 12 vials
- check16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 20 vials
Insulin Syringes (U‑100, 1 mL):
- check8 weeks: 12 syringes (average ~1.5/week)
- check12 weeks: 24 syringes (average ~2/week)
- check16 weeks: 40 syringes (average ~2.5/week)
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- check8 weeks (6 vials): 12 mL → 2 × 10 mL bottles
- check12 weeks (12 vials): 24 mL → 3 × 10 mL bottles
- check16 weeks (20 vials): 40 mL → 4 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
- checkPer week: 2 swabs (1 injection day)
- check8 weeks: 16 swabs → recommend 1 × 100‑count box
- check12 weeks: 24 swabs → recommend 1 × 100‑count box
- check16 weeks: 32 swabs → recommend 1 × 100‑count box
Mechanism of Action (MOA)
Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection [1][2]. The molecule is a balanced agonist at the GIP receptor and a biased partial agonist at the GLP-1 receptor — the GLP-1 affinity is roughly five-fold lower than native GLP-1, an apparently deliberate design choice that may reduce receptor desensitization and limit GI side-effect intensity relative to pure GLP-1 agonism. The dual mechanism produces additive metabolic effects: GLP-1 receptor activation in arcuate hypothalamic POMC and AgRP neurons reduces appetite and food intake, slows gastric emptying, and enhances glucose-dependent insulin secretion; GIP receptor activation appears to augment satiety, improve insulin sensitivity in adipose tissue, and may potentiate the anti-nausea adaptation seen with chronic dosing [2]. The injection is delivered subcutaneously into the abdomen, thigh or upper arm using a fixed-dose autoinjector pen, with rotation of sites recommended. Plasma concentrations rise to peak around 24–48 hours and the long half-life produces stable steady-state exposure with weekly dosing; full pharmacokinetic steady state is reached after about 4 weeks. The titration protocol used in SURPASS and SURMOUNT begins at 2.5 mg weekly for 4 weeks as a tolerance-building dose, then escalates monthly through 5, 7.5, 10, 12.5 and 15 mg, with most patients stabilizing at 10–15 mg for maximum weight-loss benefit. For type 2 diabetes, 5 mg is often sufficient to achieve target HbA1c; for obesity indications, higher maintenance doses tend to produce dose-proportional additional weight loss. Downstream metabolic effects are extensive. In the SURPASS Phase 3 type-2-diabetes program, tirzepatide produced HbA1c reductions of 1.9–2.6% from baselines of 7.9–9.5% across the SURPASS-1 through SURPASS-5 trials, with SURPASS-2 showing superiority over semaglutide 1 mg on both HbA1c and weight endpoints [3]. Body-composition substudies using DXA in SURMOUNT-1 found that approximately 75% of weight loss on tirzepatide is fat mass, with significant visceral-adipose-tissue reductions and improvements in liver fat. Beyond glucose and weight, tirzepatide reduces systolic blood pressure by 7–9 mmHg, lowers triglycerides by 22–28% and reduces apolipoprotein B; the SURMOUNT-MMO cardiovascular outcomes trial is expected to report in 2027 and will define MACE benefit. Tirzepatide has also shown benefit in obstructive sleep apnea (SURMOUNT-OSA), heart failure with preserved ejection fraction (SUMMIT) and MASH (SYNERGY-NASH), supporting a broader cardiometabolic value proposition.
Clinical Trial Efficacy Highlights
- starSURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized 2,539 adults with obesity (BMI ≥30 or ≥27 with comorbidity) without diabetes to tirzepatide 5, 10 or 15 mg weekly or placebo for 72 weeks. Mean weight reduction was 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) versus 3.1% with placebo, with 50%, 55% and 57% of participants losing ≥20% of body weight on the respective active arms [1].
- starSURMOUNT-2 (Garvey et al., Lancet 2023) enrolled 938 adults with obesity plus type 2 diabetes. Tirzepatide produced mean weight reductions of 13.4% (10 mg) and 15.7% (15 mg) at 72 weeks compared to 3.3% with placebo, while reducing HbA1c by 2.1% versus 0.5% — proving that weight-loss efficacy persists in the harder-to-treat T2D population [4].
- starSURPASS-2 (Frias et al., NEJM 2021) compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with T2D over 40 weeks. Tirzepatide 15 mg reduced HbA1c by 2.30% versus 1.86% with semaglutide and produced 11.2 kg of weight loss versus 5.7 kg — the first GLP-1-class drug to be clearly outperformed [3].
- starSURMOUNT-3 (Wadden et al., Nature Medicine 2023) enrolled patients who had already lost ≥5% weight on a 12-week intensive lifestyle program, then randomized them to tirzepatide or placebo. The active arm lost an additional 18.4% over 72 weeks vs +2.5% regain on placebo, demonstrating tirzepatide can extend benefit beyond lifestyle intervention plateau.
- starSURMOUNT-4 (Aronne et al., JAMA 2024) showed that participants who continued tirzepatide after a 36-week run-in maintained their weight loss, while those switched to placebo regained 14% of body weight, confirming continued therapy is required to preserve benefit.
- starSURMOUNT-OSA (Malhotra et al., NEJM 2024) demonstrated that tirzepatide reduced the apnea-hypopnea index by roughly 25–30 events/hour in obese adults with moderate-to-severe OSA, with about half achieving disease resolution — establishing the first pharmacologic standard-of-care for obesity-driven sleep apnea.
- starSUMMIT (Packer et al., NEJM 2024) showed tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38% in patients with obesity-related HFpEF, suggesting cardiovascular benefit beyond glycemia and weight.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal events were the most common adverse events in SURMOUNT-1, with nausea reported in 24–33% of active-arm participants vs 9.5% with placebo, diarrhea in 19–23% vs 7.3%, and vomiting in 8–12% vs 1.7%. Most were mild-to-moderate and concentrated during titration; <5% discontinued for GI reasons [1].
- warningConstipation occurred in 11–17% of participants, often persisting beyond the titration period and managed with hydration, fiber and osmotic laxatives. Dyspepsia, abdominal pain and decreased appetite were also reported at rates of 5–12% [1].
- warningHeart-rate increases of 2–4 beats per minute on average — slightly less pronounced than seen with retatrutide but consistent with incretin class effect. No clinically meaningful QT prolongation was observed across the SURPASS and SURMOUNT programs [1][3].
- warningAcute pancreatitis was reported in <0.4% of participants in SURMOUNT-1, broadly consistent with background rate in obese populations; FDA labeling carries a warning to discontinue if pancreatitis is suspected and to use cautiously in patients with prior pancreatitis history.
- warningCholelithiasis and acute cholecystitis occurred in 1.7% of tirzepatide-treated participants vs 1.2% with placebo in pooled SURMOUNT data — a class effect of rapid weight loss combined with the bile-flow effects of GLP-1 agonism.
- warningFDA labeling includes a boxed warning regarding thyroid C-cell tumors based on rodent carcinogenicity studies. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. No causal link in humans has been established [1].
- warningHypoglycemia is uncommon as monotherapy because tirzepatide stimulates glucose-dependent insulin release, but rates increase substantially when combined with sulfonylureas or basal insulin, requiring background-therapy dose reductions [3].
- warningInjection-site reactions occurred in approximately 3–4% of participants, generally mild and self-limited. Rotation between abdomen, thigh and upper arm sites is standard practice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Tirzepatide dosage?expand_more
Tirzepatide is dosed once weekly subcutaneously, starting at 2.5 mg for 4 weeks (tolerance-building only, not therapeutic) and escalating monthly through 5, 7.5, 10, 12.5 and 15 mg. Maintenance for weight loss is typically 10–15 mg; for type 2 diabetes, 5–10 mg often suffices. Each dose step requires at least 4 weeks at the prior dose.
How is Tirzepatide different from Semaglutide?expand_more
Both are weekly incretin injections, but tirzepatide is a dual GIP/GLP-1 agonist while semaglutide is a pure GLP-1 agonist. In head-to-head SURPASS-2, tirzepatide 15 mg beat semaglutide 1 mg on HbA1c (-2.30% vs -1.86%) and weight (-11.2 kg vs -5.7 kg). Tirzepatide also produced greater weight loss in cross-trial comparisons (≈21% vs ≈15%) [3].
What are the most common side effects of Tirzepatide?expand_more
Most common are GI: nausea (24–33%), diarrhea (19–23%), constipation (11–17%) and vomiting (8–12%), concentrated during titration. Less common: injection-site reactions, gallbladder events, mild heart-rate increase. The label carries a boxed warning for thyroid C-cell tumors based on rodent data only [1].
How should Tirzepatide be reconstituted and stored?expand_more
Commercial Mounjaro/Zepbound is pre-filled and requires no reconstitution; store at 2–8 C, protect from light, and may be kept at room temperature (up to 30 C) for up to 21 days. Compounded vials reconstituted with bacteriostatic water should be refrigerated and used within 28 days; do not freeze or expose to direct sunlight.
Is Tirzepatide FDA approved?expand_more
Yes. Tirzepatide was approved by FDA in May 2022 as Mounjaro for type 2 diabetes and in November 2023 as Zepbound for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. EMA, UK MHRA, Japan PMDA and many other regulators have also approved it.
Academic References & Study Citations
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022) N Engl J Med 387:205-216. 'Tirzepatide Once Weekly for the Treatment of Obesity' (SURMOUNT-1). 20.9% weight loss at 72 weeks on 15 mg. View Scientific Paper →
Coskun T, Sloop KW, Loghin C, et al. (2018) Mol Metab 18:3-14. 'LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept'. View Scientific Paper →
Frias JP, Davies MJ, Rosenstock J, et al. (2021) N Engl J Med 385:503-515. 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes' (SURPASS-2). View Scientific Paper →
Garvey WT, Frias JP, Jastreboff AM, et al. (2023) Lancet 402:613-626. 'Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)'. View Scientific Paper →
Wadden TA, Chao AM, Machineni S, et al. (2023) Nat Med 29:2909-2918. 'Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial'. View Scientific Paper →
Aronne LJ, Sattar N, Horn DB, et al. (2024) JAMA 331:38-48. 'Continued Treatment With Tirzepatide for Maintenance of Weight Reduction' (SURMOUNT-4). View Scientific Paper →
Malhotra A, Grunstein RR, Fietze I, et al. (2024) N Engl J Med 391:1193-1205. 'Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity' (SURMOUNT-OSA). View Scientific Paper →
Packer M, Zile MR, Kramer CM, et al. (2024) N Engl J Med 392:427-437. 'Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity' (SUMMIT). View Scientific Paper →
FDA label — Zepbound (tirzepatide) injection, full prescribing information, November 2023. View Scientific Paper →